EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Sequential Disease-Modifying Therapy and Early Experience with Eplontersen in Hereditary Transthyretin Amyloidosis (p.Thr80Ala) with a Mixed Phenotype: A Case Report

Mahshid Eslami, Antonio Kösters, Nikita Ermolaev, Bernhard Gregshammer, Christina Kronberger, René Rettl, Franz Duca, Andreas A. Kammerlander, Michaela Auer-Grumbach, Roza Badr Eslam

Journal of Cardiovascular Development and Disease · 2026-11-07 · 13 (11) · 575

DOI: 10.3390/jcdd13110575 ↗
AbstractBibliografische Angaben

Abstract

Background: Hereditary transthyretin amyloidosis (ATTRv) is a progressive multisystem disease, and some patients continue to deteriorate despite disease-modifying therapy. Real-world data on sequential treatment and on eplontersen after prior gene-silencing therapy are scarce. Case Presentation: A 60-year-old man with a family history suggestive of amyloidosis presented in early 2017 with heart failure (NYHA class II–III), chronic diarrhoea and carpal tunnel syndrome. Multimodality imaging, grade 3 bone scintigraphy, exclusion of a monoclonal protein (negative immunofixation and a normal serum free light chain ratio) and genetic testing established ATTRv amyloidosis due to the p.Thr80Ala variant, and colonic and duodenal biopsies showed gastrointestinal amyloid deposits. Between 2017 and 2025 he was treated sequentially with tafamidis, patisiran and vutrisiran. Over this period the disease progressed clinically, with weight loss, worsening axonal polyneuropathy on nerve conduction studies, rising NT-proBNP (up to 3808 pg/mL) and a decline in six-minute walk distance. In July 2025, vutrisiran was replaced by eplontersen. During 15 months of follow-up, eplontersen was well tolerated and body weight increased from 54 to 57 kg. NT-proBNP fluctuated without a sustained further rise (3093 pg/mL at the switch and 3141 pg/mL at 15 months), and troponin T and renal function were unchanged, whereas diarrhoea persisted and the six-minute walk distance was 360 m. Conclusions: This case shows clinical progression of p.Thr80Ala ATTRv amyloidosis despite sequential stabiliser and small interfering RNA therapy, followed by clinical stabilisation after a switch to eplontersen. Without serum TTR measurements and in a single patient, these observations do not allow conclusions about treatment efficacy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →